RARE — Ultragenyx Pharmaceutical Inc.

Summary of Ultragenyx (RARE) Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $214 million, marking the highest quarterly revenue in the company's history.
  • Crysvita: $156 million (North America: $94 million, Latin America and Turkey: $54 million, Europe: $8 million).
  • DOJOLVI: $27 million, consistent with steady demand growth.
  • Evkeeza: $21 million, a 50% increase year-over-year.
  • MEPSEVII: $10 million.
• Operating Expenses: $289 million, including $34 million in cost of sales and $255 million in combined R&D and SG&A expenses.
• Net Loss: $92 million, or $0.90 per share.
• Cash Position: $436 million in cash and marketable securities, with net cash used in operations decreasing to $97 million.

2. Strategic Updates and Business Highlights:

• The company is preparing for two potential gene therapy launches: DTX-401 for Glycogen Storage Disease Type Ia and UX-111 for Sanfilippo syndrome type A, with PDUFA dates of August 23 and September 19, respectively.
• Continued strong performance of existing products, with a focus on expanding patient access and finding new patients.
• The commercial team is leveraging its global infrastructure to support upcoming launches and ongoing product performance.
• Positive clinical data for DTX-401 and UX-111, with significant improvements reported in patients' conditions.

3. Forward Guidance and Outlook:

• The company reaffirmed its full-year revenue guidance, expecting continued double-digit growth from existing products and contributions from potential upcoming launches.
• Management expressed confidence in achieving profitability by 2027, driven by revenue growth, disciplined expense management, and potential monetization of priority review vouchers (PRVs) associated with DTX-401 and UX-111.

4. Bad News, Challenges, or Points of Concern:

• The company faces the challenge of managing expenses, with total operating expenses significantly exceeding revenue for the quarter.
• Regulatory uncertainties remain, particularly regarding the need for additional clinical data for setrusumab (UX-143) and the potential requirement for a new randomized study before FDA approval.
• There is ongoing concern regarding the performance of the placebo group in clinical trials, particularly for the Angelman syndrome study, which could impact regulatory outcomes.

5. Notable Q&A Insights:

• Angelman Syndrome Study: Management clarified that the FDA has agreed to a shared alpha approach for the primary endpoints, allowing either endpoint to be positive for filing.
• MDRI Endpoint Sensitivity: The MDRI is expected to be more sensitive in detecting clinical changes compared to traditional endpoints, which could enhance the chances of demonstrating efficacy.
• Launch Readiness: The company is well-prepared for the upcoming launches, leveraging existing infrastructure and experience from previous product launches.
• Market Size Estimates: For DTX-401, the addressable population is estimated at 1,500-2,000 in the U.S., while for UX-111, it is around 600-1,000 patients in the U.S., with urgency highlighted for both conditions.

Overall, Ultragenyx is positioned for significant growth with upcoming product launches and strong existing product performance, though it must navigate regulatory challenges and manage expenses effectively to achieve profitability.